Earnings season continues, with healthcare companies set to report next week Among them is Pfizer, whose stock has corrected significantly of late Based on the company's strong...
The biotech sector looks ripe for a rebound Vertex Pharmaceutical has been a strong outperformer since 2022 Strategic advantages and strong financial health should allow VRTX to...
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely looking...
Inflation worries continue to weigh on equity markets Earnings season will likely increase volatility ETFs offer investors ability to diversify Earnings season has started with...
The COVID-19 pandemic highlighted the importance of health care and the role biopharma companies play in drug and vaccine development. As a result, the sector grew tremendously...
Wall Street seems to have eyes only for two things at the moment: the potential next move by the Federal Reserve and geopolitical tensions between Russia and Ukraine. Meanwhile,...
A number of health-care and biotech shares have recently been in the spotlight. In early October, Merck (NYSE:MRK)—covered in early November—gave a positive update on...
Last month, Investor's Business Daily rated Vertex Pharmaceuticals (NASDAQ:VRTX) number four on its list of the best ESG stocks, awarding the company high marks for its...
Stocks on Wall Street ended the week on a high note, with indexes looking past inflation worries as most major averages closing within sight of their recent records. The NASDAQ...
Another earnings season is here. The financial sector typically gets the most attention in the first days of quarterly reporting. Yet, many other closely-followed companies in...